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Abstract 
Background: The elderly are considered as special population, as they differ from younger adults in terms of comor-
bidity, polypharmacy, pharmacokinetics, vulnerability to drug–drug interactions and adverse drug reactions. Despite 
the fact that the elderly patients are at high risk of having drug interaction and potential adverse outcomes, studies 
in this regard are scarce in resource limited settings like Ethiopia. The aim of this study was to assess the prevalence 
and determinants of potential drug–drug interaction in elderly patients admitted to medical ward of Ayder Referral 
Hospital in Northern Ethiopia.
Methods: A cross sectional study was conducted among elderly inpatients aged 60 years and above. The study was 
conducted from February to May 2014. Prescribed drugs being taken concurrently for at least 24 h were included and 
checked for drug–drug interaction using Micromedex® 2.0 online drug reference. Data were analyzed using statistical 
software, statistical package for social sciences for windows version 20. Logistic regression model was used to analyze 
factors associated with occurrence of drug interaction. P value of <0.05 was considered statistically significant.
Results: A total of 140 patients were participated in the study. The mean age (±standard deviation) of participants 
was 68 (±7) years. Majority (61.4 %) of patients were diagnosed with cardiovascular and/or renal diseases. A total 
of 814 drugs were prescribed with a mean of 6 (±4) medications per patient during a 13 (±9) days of hospital stay. 
About two-third (62.2 %) of the respondents were exposed to at least one potential drug–drug interaction. Among 
these 3.6, 32.9 and 25.7 % of patients had taken contraindicated drug combination, at least one major and at least one 
moderate drug–drug interaction, respectively. Patients with five or more prescribed medications were four times at 
risk of having drug–drug interaction (P = 0.00; adjusted odds ratio 4.047; 95 % confidence interval 1.867–8.775).
Conclusion: Drug–drug interaction in elderly patients was common in this resource limited set-up. Awareness crea-
tion and clinical pharmacist involvement in minimizing the risk associated with potentially harmful drug combina-
tions are needed.
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Background
The ageing process is biological reality that has its own 
dynamic, largely beyond human control. The age of 65 
and above, roughly equivalent to retirement ages in most 
developed countries is said to be the beginning of old 
age. However, this is not adapted well to the situation in 
developing countries like Africa. The United Nation (UN) 
agreed cutoff is 60 and above to refer to the older popula-
tion [1] and this definition has gained acceptance in Ethi-
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The elderly differ from young adults in terms of comor-
bidity, polypharmacy, pharmacokinetics and greater vul-
nerability to adverse drug reactions (ADRs) [3]. Clinical 
trials are usually done in young adults excluding the elderly 
population. This brings a challenge in caring the elderly as 
findings obtained from trials may not be applicable to all 
real patients [4]. Along with age related gradual changes, 
the pharmacodynamics and pharmacokinetics of drugs in 
the elderly is altered. There are physiological changes that 
affect how medicines are handled, including alterations in 
drugs absorption, volumes of distribution, metabolism and 
clearance which can prolong half-life, increase potential 
for drug toxicity and the likelihood of ADRs [5–7]. In addi-
tion, there is alteration in drug response or sensitivity in 
the elderly probably due to changes in receptor numbers, 
changes in receptor affinity and age-related impairment of 
homeostatic mechanisms [4, 8].
Drug–drug interactions (DDIs) occurs when the effects 
of one drug is altered by another concomitantly adminis-
tered drug [9]. The effect of a DDI might be apparent as 
decline in therapeutic effect of a drug, increased occur-
rence of ADRs and compromised treatment outcomes [10, 
11]. Advanced age, polypharmacy and multiple prescribers 
have been identified as risk factors for occurrence of poten-
tial drug interactions [12]. DDIs are more likely to happen 
in the elderly because they tend to use multiple medications 
and have altered pharmacokinetics [6, 13]. A systematic lit-
erature review by Saedder et al. also identified number of 
drugs as the most frequently documented independent 
patient-related risk factor for serious ADRs in both the gen-
eral adult population as well as in the elderly [14].
Drug interactions are considerable cause of ADRs and 
hospital admission. The incidence of DDI related ADRs 
in the elderly had been estimated to ranges from 4.5 to 
6.5 % [15, 16]. In a systematic review and meta-analysis 
of observational study, DDI accounted for the 1.1 % hos-
pital admissions and 0.1 % hospital visits [17]. More than 
half of all hospitalizations due to ADR had occurred in 
the elderly patients [18, 19]. Furthermore, DDI is asso-
ciated with increased length of hospital stay and other 
added healthcare costs [20–22]. Despite the fact that the 
elderly patients are at high risk of having drug interaction 
and potential adverse outcomes, studies in this regard 
are scarce in resource limited settings like Ethiopia. The 
aim of this study was to assess the prevalence and deter-
minants of potential DDIs in elderly patients admitted 
to medical ward of Ayder Referral Hospital (ARH) in 
Northern Ethiopia.
Methods
The study was conducted from February to May 2014 
in ARH located in Mekelle city of Tigray Regional State, 
Northern Ethiopia. ARH is a teaching and the highest 
level medical facility in the northern part of the country. 
It provides general inpatient and outpatient services in 
four major departments (Internal Medicine, Pediatrics, 
Surgery, Gynecology and Obstetrics) and other specialty 
units [23]. A cross sectional study design was employed 
to assess drug–drug interactions in elderly patients. For 
this study, individuals aged 60 and above were included 
based on the UN’s definition of elderly [1] and this is the 
accepted cutoff for elderly population in Ethiopia [2]. Par-
ticipants’ medical record was reviewed every 2 days from 
date of admission to date of discharge to see any added 
or discontinued treatments. Prescribed drugs being taken 
concurrently for at least 24 h were included and checked 
for drug–drug interaction using Micromedex® 2.0 online 
drug reference [24]. Micromedex® is medical software 
which gives evidence-based drug information about 
DDIs and potential ADRs. It categorizes drug combina-
tions into contraindicated, major, moderate, and minor 
level of interaction based on the mortality and morbidity 
probabilities on patients.
Definitions
Concurrent or concomitant drugs Is defined as the con-
current use of drugs as prescribed by one or more differ-
ent medical doctors not necessarily on the same day [25].
Comorbidity Is the presence of more than one distinct 
medical condition in an individual [26].
Contraindicated DDI The drug-pair is contraindicated 
for concurrent use [24].
Major DDI The interaction may have risk of death and/
or require medical intervention to minimize or prevent 
some serious negative outcomes [24].
Moderate DDI It may have harmful effect on patient’s 
condition and can require change in the prescription 
[24].
Polypharmacy Is defined as the use of many drugs at the 
same time or the administration of an excessive number 
of drugs [27]. There is no standard cut point with regard 
to the number of medications that is agreed upon for the 
definition of polypharmacy. In this study, polypharmacy 
was operationalized to mean five drugs or more.
A sample of 140 elderly patients was studied. The sam-
ple size was determined using the formula for estimation 
of single proportion [n  =  (Z·α/2)2 p(1  −  p)/d2] where 
Z  =  standard normal variable at 95  % confidence level 
(1.96), p =  the prevalence of potential drug–drug inter-
action assumed to be 50  % and finally adjusted using 
correction formula for finite population. Study par-
ticipants were selected by systematic random sampling 
techniques. List of admitted elderly patient at a particu-
lar time was considered as sampling frame. Sampling 
interval was obtained by dividing the number of elderly 
patients likely to be admitted during the study period 
Page 3 of 8Teka et al. BMC Res Notes  (2016) 9:431 
divided by the sample size which gives 2 (300/140 = 2). 
The first patient was selected randomly and every other 
patient was included in the study.
Data were collected using a structured and pretested 
format that contains patient identification, medical 
profile and drugs prescribed. The data collectors were 
six final year pharmacy students, trained on how to 
approach study participants, ask for informed consent, 
abstract data from patient records and maintain the con-
fidentiality of the collected data. Prior to the actual data 
collection, a pretest was done on six elderly patients (not 
included in this study) to check the practicability of the 
data collection format and procedures and to assess the 
performance of data collectors.
The evaluation of drug–drug interaction and data 
analysis was done by the investigators. Micromedex® 
2.0 online drug reference [24] was used to check and 
describe the types of drug–drug interaction. Data were 
analyzed using statistical package for social sciences; for 
windows version 20 statistical software. The data were 
first checked for completeness then edited, cleaned and 
entered into the software. Descriptive statistics (frequen-
cies, percentage, mean and standard deviation) were 
used to present counts, proportions and averages. Binary 
logistic regression model was used to analyze factors 
associated with occurrence of drug interaction. Output 
of the logistic regression was expressed as adjusted odds 
ratios at 95 % confidence intervals. P value of <0.05 was 
considered statistically significant.
Results
The medical records of 140 patients aged 60  years and 
above were utilized for the study. The mean age (±SD) 
of participants was 68 (±7) years. Almost half (52.1  %) 
of the study participants were male. The mean hospital 
stay of patients was 13 (±9) days. 38 % of the participants 
had comorbid conditions while 17.8 of them had a single 
diagnosis. Majority (61.4 %) of the patients had a diagno-
sis of cardiovascular (CV) and/or renal disease. The com-
mon CV diseases were heart failure (22.8  %), followed 
by hypertension (20 %) while 6.4 % of patients had both 
medical conditions. Infectious diseases were diagnosed 
in 58.6 % of patients. Pneumonia accompanied for 32 %, 
followed by tuberculosis (15  %) and urinary tract infec-
tion (5.7  %). The third ranked class of diagnosis was 
hematologic and thromboembolic disorders.
A total of 814 drugs were prescribed during the mean 
hospital stay of 13 (±9)  days, with an mean of 6 (±4) 
medications per patient. Fifty-nine (42.2 %) patients had 
<5 prescribed drugs while 40 and 17.8 % of them had 5–8 
and more than 8 prescribed drugs, respectively. Ceftriax-
one was the most commonly used medication, prescribed 
in 55.75 % of the participants.
According to Micromedex® 2.0 online drug refer-
ence, nearly two-third (62.2  %) of the participants were 
exposed to at least one potential DDI. Among those 3.6, 
32.9 and 25.7 % of elderly patients were prescribed a con-
traindicated drug combination, at least one major and 
at least one moderate DDI respectively. Clarithromycin 
with either simvastatin or ciprofloxacin was the only con-
traindicated drug combination in this study (Table 1).
The most frequently prescribed major DDIs were the 
combination of aspirin with either heparin or clopi-
dogrel; warfarin with quinolone and macrolide antibiot-
ics; and spironolactone with enalapril (Table 2).
There was no significant difference in the occurrence of 
DDI with respect to age, sex, presence of co-morbidities 
and length of hospital stay. DDI was found significantly 
associated with increase in number of drugs (polyphar-
macy) (P =  0.00; adjusted odds ratio 4.047; 95  % confi-
dence interval 1.867–8.775) (Table 3).
Discussion
The mean (±SD) number of drugs prescribed per patient 
in this study was 6 (±4) which is almost similar to a study 
in Taiwan [28] 5.8  ±  2.4 but lower than study reports 
from Puducherry [29], India [30]; which was 7.61 ± 3.37 
and 9.15  ±  0.03, respectively. These differences could 
be due to the difference in study set-up, health insur-
ance policy, and difference in burden of co-morbidity 
and medication use pattern in these settings. In the cur-
rent study, there is similar burden of infectious diseases 
(58.6  %) and cardiovascular diseases (61.4  %), where 
as in developed countries non-communicable diseases 
Table 1 List of contraindicated drug combinations and potential risk
a  Documentation based on available studies or reports: good, studies strongly suggest that the interaction exists except proof of well-controlled studies; 
fair, available evidences are poor, but the interaction is suspected on the basis of pharmacologic considerations; or, evidences are good for an interaction of 
pharmacologically similar drug [24]
Drug combinations Number of patients Documentationa Potential risks
Clarithromycin simvastatin 3 Good Increased risk of myopathy or rhabdomyolysis
Clarithromycin ciprofloxacin 1 Fair Increased risk of QT interval prolongation
Total 4
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Table 2 List of major drug–drug interactions with their potential risks
Interacting drugs Number of patients Documentationa Potential risks
Anti TB(HRZ) + phenytoin 2 Good Decreased phenytoin and/or rifampin exposure
Aspirin + cimetidine 1 ND
Aspirin + clopidogrel 5 Fair Increased risk of bleeding
Aspirin + enoxaparin 2 Good Increased risk of bleeding
Aspirin + fluoxetine 1 Good Increased risk of bleeding
Aspirin + omeprazole 1 ND
Ciprofloxacin + amitriptyline 1 Fair Increased risk of QT interval prolongation
Ciprofloxacin + doxorubicin 1 Fair Increased doxorubicin exposure
Clarithromycin + amitriptyline 1 Fair Increased risk of QT-interval prolongation
Clarithromycin + amlodipine 1 Excellent Increased amlodipine exposure
Clarithromycin + digoxin 2 Excellent Digoxin toxicity (nausea, vomiting, arrhythmias)
Clarithromycin + nifedipine 1 Moderate fair Increased nifedipine plasma concentrations
Clarithromycin + tramadol 3 Fair Increased risk for seizures, serotonin syndrome, and opioid-related 
toxicity
Clarithromycin + atorvastatin 1 Good Increased risk of myopathy or rhabdomyolysis
Clopidogrel + cimetidine 3 Fair Reduction in clinical efficacy of clopidogrel
Clopidogrel + diclofenac 1 Excellent An increased risk of bleeding
Clopidogrel + omeprazole 1 Excellent Reduction in clinical efficacy of clopidogrel and increased risk for 
thrombosis
Cyclophosphamide + allopurinol 3 Good Cyclophosphamide toxicity (bone marrow suppression, nausea, 
vomiting)
Cyclophosphamide + doxorubicin 3 Fair Increased risk of cardiomyopathy
Heparin + aspirin 14 Fair Increased risk of bleeding
Heparin + enoxaparin 1 Fair Increased risk of bleeding
Heparin + clopidogrel 4 Fair Increased risk of bleeding
Heparin + diclofenac 1 Fair Increased risk of gastrointestinal bleeding
Heparin + indomethacin 3 Excellent Increased risk of gastrointestinal bleeding; reduced effectiveness of 
indomethacin for the treatment of patent ductus arteriosus
Hydralazine + metformin 1 ND
Hydralazine + norfloxacin 1 ND
Insulin + norfloxacin 2 Fair Changes in blood glucose and increased risk of hypoglycemia or 
hyperglycemia
Insulin + ciprofloxacin 2 Fair Changes in blood glucose and increased risk of hypoglycemia or 
hyperglycemia
Potassium chloride + enalapril 2 Good Hyperkalemia
Simvastatin + azithromycin 2 Good An increased risk of rhabdomyolysis
Simvastatin + ciprofloxacin 2 Good Increased risk of myopathy or rhabdomyolysis
Spironolactone + digoxin 2 Good Increased digoxin exposure
Spironolactone + enalapril 10 Good Hyperkalemia
Spironolactone + potassium chloride 4 Fair Hyperkalemia
Tramadol + chlorpromazine 2 Fair Increased risk of seizures
Tramadol + amitriptyline 1 Fair Increased risk of seizures, serotonin syndrome (hypertension, 
hyperthermia, myoclonus, mental status changes), opioid toxicity, 
and increased concentrations of tramadol and decreased con-
centrations of tramadol active metabolite
Warfarin + aspirin 3 Fair Increased risk of bleeding
Warfarin + azithromycin 2 Good Increased risk of bleeding
Warfarin + ciprofloxacin 3 Good Increased risk of bleeding
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including cardiovascular diseases are more common than 
infectious diseases. Unlike in developed countries, health 
insurance policy for the elderly which provides more 
access to medications is not introduced in this study set-
up. In this study, 62.2 % of the respondents were exposed 
to at least one potential DDI [including contraindicated 
(3.6 %), major (32.9 %) and moderate (25.7 %)]. The prev-
alence of major and moderate DDI in the current study is 
in line with the findings by Luca et al. [31] and Lea et al. 
[32], which reported a prevalence of 63.5, 60.5 % potential 
DDIs respectively. In contrast to this study, lower preva-
lence of DDIs was reported from other studies focusing 
on elderly outpatients [33–35]. This indicates that drug 
interactions are more common in inpatients set-up as 
compared to outpatients probably due to the difference 
in number of drugs prescribed per patient.
In this study polypharmacy (taking five drugs or more) 
was identified as predictor for the occurrence of DDI 
(P = 0.00; AOR 4.047; 95 % CI 1.867–8.775). A number 
of other studies have also identified an increase num-
ber of medications a predictor of DDI in the elderly [6, 
9, 15, 30, 34–41]. A study from Brazil reported that the 
potential drug interaction risk when patients are taking 
2–3, 4–5 and 6–7 medications was 39, 88.8 and 100  %, 
respectively [36]. Nearly 50 % of elderly patients take one 
or more medications that are not medically necessary 
[37]. However, in the context of the elderly, polyphar-
macy does not necessarily mean inappropriate. A num-
ber of elderly patients may be prescribed combination of 
drugs to achieve synergic therapeutic response. As the 
use of many drugs in the elderly is an avoidable due to 
the comorbidities they have, it is important not to dis-
card important medications because of the potential risk 
of drug interactions. Many of the drug interactions can 
be minimized by using alternative medications but those 
that are not require awareness of the interaction to allow 
Table 2 continued
Interacting drugs Number of patients Documentationa Potential risks
Warfarin + clarithromycin 3 Good Increased risk of bleeding
Warfarin + metronidazole 6 Good Increased risk of bleeding
Total 105
a  Documentation based on available studies or reports: excellent, the interaction has been clearly demonstrated in well-controlled studies; good, studies strongly 
suggest that the interaction exists except proof of well-controlled studies; fair, available evidences are poor, but the interaction is suspected on the basis of 
pharmacologic considerations; or, evidences are good for an interaction of pharmacologically similar drug [24]
ND not documented, Anti TB (HRZ) anti tuberculosis (isoniazid/rifampicin/pyrazinamide)
Table 3 Statistical association of variables with drug–drug interaction
DDI drug–drug interaction
a  Statistically significant association
Variable Category DDI P value Adjusted odds ratio
No Yes
Sex Male 28 45
Female 25 42 0.531 0.782 (0.363–1.686)
Total 53 87
Age 60–69 26 50
70–79 18 30 0.858 0.927 (0.406–2.12)
>80 9 7 0.143 0.392 (0.112–1.373)
Total 53 87
Comorbidities No 15 10
Yes 38 77 0.241 0.557 (0.209–1.483)
Total 53 87
Hospital stay (days) <10 35 38
≥10 18 49 0.168 0.168 (0.795–3.726)
Total 53 87
Number of drugs (polypharmacy) <5 35 24
≥5 18 63 0.000a 4.047 (1.867–8.775)
Total 53 87
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for proper management and appropriate dose adjust-
ment. In reality however we must be knowledgeable not 
only about DDIs; indeed, a broad understanding of how 
to use various drugs safely in our patients is essential.
The DDI in the current study are theoretical or poten-
tial DDIs. Though the incidence of actual DDIs is lower 
than that of potential DDIs, some studies have found as 
high as 25–47 % clinically relevance potential DDIs in the 
elderly [33, 41]. The occurrence of clinically important 
interactions depends in the presence of specific risk fac-
tors such as polypharmacy, comorbidity, age, therapeutic 
range and dosage of the drug [42]. A research has clearly 
established a strong relationship between polypharmacy 
leading to DDI and negative clinical consequences [14, 
37]. Thus, the current study is important to make aware-
ness on the dangerous potential interactions that could 
have negative clinical consequences and identify risky 
groups.
In this study a contraindicated drug combination was 
observed in four (3.6 %) patients. These interactions were 
involving clarithromycin with either simvastatin or cip-
rofloxacin. In a panel of experts, these interactions were 
among the highly clinically significant drug–drug inter-
actions identified as contraindicated for concurrent use 
[43]. The interaction between clarithromycin and sim-
vastatin increases the risk of myopathy or rhabdomy-
olysis [24, 43] and myopathy was the third commonest 
ADR caused by DDI next to gastrointestinal bleeding 
and hyperkalemia [15]. Concurrent use of clarithromycin 
and ciprofloxacin is contraindicated due to the increased 
risk of QT interval prolongations [24, 43]. Probably these 
interactions can be avoided with the use of alternative 
antibiotics with similar spectrum of activity but less 
potential for interactions.
The most frequently prescribed major DDIs in the cur-
rent study were the combination of aspirin with anti-
coagulants (heparin or warfarin) and/or clopidogrel; 
warfarin with antibiotics and spironolactone with enal-
april in decreasing order of prevalence. Low-dose aspirin 
with clopidogrel and/or anticoagulants is increasingly 
prescribed in combinations to the elderly to prevent 
atherothrombotic events. A number of studies have iden-
tified these interactions responsible for the greatest num-
ber of serious bleedings [15, 30, 39, 44]. However, these 
combinations are sometimes unavoidable and might be 
indicated. Thus, careful monitoring and evaluation of the 
risk of actual drug-interaction and benefits of continu-
ing both medications is vital. When co-administration of 
these drugs is required laboratory values such as interna-
tional normalized ratio, signs and symptoms of bleeding 
should be closely monitored.
Co-administration of potassium sparing diuretic 
(spironolactone) with potassium supplements or 
angiotensin converting enzyme (ACE) inhibitors like 
enalapril where observed in this study. Concomitant use 
of these agents increases the risk of hyperkalemia and the 
elderly are more sensitive to this adverse effect. Other 
studies also reported these combinations as one of the 
clinically relevant DDI [15, 44–47]. A nested case control 
study by Juurlink et al. [47], showed that elderly patients 
treated with ACE inhibitor admitted with hyperkalemia 
were about 20 times more likely to have been treated 
with potassium sparing diuretic (adjusted odds ratio 20.3; 
95 % confidence interval 13.4–30.7).
Many of the potential DDI in the elderly can be avoided 
with close patient monitoring or the use of alternative 
medications. However, it may be difficult for clinicians to 
memorize the thousands of DDIs and their clinical sig-
nificance. Clinical pharmacist can play a role in identifi-
cation and monitoring of potential DDIs hence to make 
appropriate dosage or therapy adjustments. Studies are 
conflicting whether clinical pharmacist interventions 
such as pharmaceutical care and educational campaigns 
in improving distal health outcomes [37, 48, 49]. How-
ever, overall improvement in quality of prescribing, use of 
appropriate polypharmacy hence reduced potential DDIs 
were observed [37, 49]. Indeed, decision support systems 
and information technologies are nowadays increasingly 
utilized to prevent severe DDIs. Despite the alert fatigue 
that has been identified as a major limitation in using 
these technologies, clinical pharmacist assisted comput-
erized decision support systems was found to be efficient 
and offer an opportunity to detect potential DDIs [50].
The current study provides insight into the prevalence 
of potential DDIs in elderly inpatients in a resource con-
strained setting. In addition, it was possible to identify 
polypharmacy as a risk factor for the occurrence of DDI 
in the elderly which have been observed in other studies. 
However, the study has some limitations: one the study 
was done on small number of elderly patients compared 
to other studies. Second, being a cross sectional study 
which was carried out at one time point, it was not possi-
ble to see the outcome of the potential DDI or the actual 
occurrence of the interactions from a clinical viewpoint. 
Further longitudinal studies using larger number of par-
ticipants are necessary.
Conclusion
The finding of present study reveals that nearly two-
third of the elderly patients are exposed to at least one 
potential DDIs. Elderly patients on five or more medi-
cations needs close monitoring as they are four times 
at higher risk of having DDIs (Additional file  1). Iden-
tifying and preventing potentially harmful DDIs is a 
critical component of a pharmacist’s mission and the 
clinical pharmacist must remain vigilant in monitoring 
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potential DDIs and making appropriate dosage or ther-
apy adjustments.
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